ASLN - ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis | Benzinga
- ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveys
- Register here to attend the webinar event on October 24, 2023 at 11:00 am ET
SAN MATEO, Calif. and SINGAPORE, Oct. 18, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will co-host a panel discussion with a leading Clinical Research Organization (CRO), "The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has Changed in the Seven Years Following Dupilumab's Introduction", that will feature Key Opinion Leaders (KOLs) Jonathan Silverberg, MD, PhD, MPH (The George Washington University School of Medicine and Health Sciences), and April W. Armstrong, MD, MPH (UCLA Health).
The webinar event will include presentations by ASLAN and the CRO followed by a panel discussion with both KOLs, on the changes in the clinical trial and treatment landscape in atopic dermatitis (AD), the impact these changes have on clinical data and new therapies, and potential solutions for optimizing AD trials.
ASLAN management will discuss data from the Phase 2b TREK-AD study of eblasakimab and will present new market research from surveys of AD patients and prescribers on their views of current and future therapies.
Register here to attend the webcast from 11:00 am – 12:00 pm ET on Tuesday, October 24, 2023, or watch the replay of the event.
About Jonathan Silverberg, MD, PhD, MPH
Jonathan Silverberg is a Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis.
Dr. Silverberg completed his undergraduate and medical school training as a part of the highly selective dual B.A./M.D. program at State University of New York Downstate Medical Center, in Brooklyn. Dr. Silverberg also received ...